Endocrine Abstracts

Background: Given the possible association between dipeptidyl peptidase-4 (DPP-4) inhibitor and risk of diabetic retinopathy (DR), we examined whether DPP-4 inhibitors are beneficial or harmful for DR compared with other glucose-lowering agents.Methods: From a Korean population-based cohort, we identified 67,743 adults with type 2 diabetes treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was done for comparative groups: eve...

Background: We aimed to explore the relationship between continuous glucose monitoring (CGM)-derived indicators and the presence of albuminuria taking circadian features into consideration concurrently in Insulin-using patients with type 2 diabetes.Methods: We analyzed data from 129 insulin-treated type 2 diabetes patients in Korea University Ansan Hospital. Over 10 days, we collected time-series data using Dexcom G6, Fitbit, and food diaries, along with...

Recently, dipeptidyl peptidase-IV (DPP-IV) inhibitor, a major anti-hyperglycaemic agent, has received substantial attention as a possible therapeutic target for inflammatory diseases such as atherosclerosis. However, the direct molecular mechanisms through which DPP-IV inhibitor mediates anti-inflammatory effects in vascular endothelial cells have not been clarified. The effects of the DPP-IV inhibitor, gemigliptin, were analysed in human umbilical vein endothelial cells (HUVE...